Skip Navigation LinksHome > December 2012 - Volume 19 - Issue 12 > A standardized phytopreparation from an Indian medicinal pla...
doi: 10.1097/GME.0b013e318256b6ae
Original Articles

A standardized phytopreparation from an Indian medicinal plant (Dalbergia sissoo) has antiresorptive and bone-forming effects on a postmenopausal osteoporosis model of rat

Khedgikar, Vikram MSc1; Gautam, Jyoti MSc1; Kushwaha, Priyanka MSc1; Kumar, Avinash MSc1; Nagar, Geet K. BSc1; Dixit, Preety MSc2; Chillara, Raju MSc2; Voruganti, Swathi MSc3; Singh, Sheelendra P. MSc3; Uddin, Wahaj MSc3; Jain, Girish K. PhD3; Singh, Divya PhD1; Maurya, Rakesh PhD2; Chattopadhyay, Naibedya PhD1; Trivedi, Ritu PhD1

Supplemental Author Material
Collapse Box


Objective: The aim of this study was to evaluate the skeletal effects of an extract made from the leaves and pods of Dalbergia sissoo (butanol-soluble standardized fraction [BSSF]) on ovariectomized rats, a model for postmenopausal osteopenia.

Methods: Adult Sprague-Dawley rats were ovariectomized and administered BSSF (50 and 100 mg/kg per day) or 17β-estradiol orally for 12 weeks. The sham-operated group and the ovariectomy + vehicle group served as controls. Bone microarchitecture, bone turnover markers (serum osteocalcin and C-telopeptide fragment of collagen type I), biomechanical strength, new bone formation (based on mineral apposition rate and bone formation rate), and skeletal expressions of osteogenic and resorptive gene markers were studied. Uterine histomorphometry was used to assess estrogenicity. Bioactive marker compounds in BSSF were analyzed by high-performance liquid chromatography. One-way analysis of variance was used to test the significance of effects.

Results: In comparison with ovariectomized rats treated with vehicle, BSSF treatment in ovariectomized rats resulted in an improved trabecular microarchitecture of the long bones, increased biomechanical strength parameters of the vertebra and femur, decreased bone turnover markers (osteocalcin and type I collagen) and expression of skeletal osteoclastogenic genes, and increased new bone formation and expression of osteogenic genes in the femur. Overall, the osteoprotective effects of BSSF were comparable to those of 17β-estradiol. BSSF did not exhibit uterine estrogenicity. Analysis of marker compounds revealed the presence of osteogenic methoxyisoflavones, including caviunin 7-O-[β-D-apiofuranosyl-(1→6)-β-D-glucopyranoside] (a novel compound), biochanin A, and pratensin.

Conclusions: Oral doses of BSSF in the preclinical setting are effective in preventing estrogen deficiency–induced bone loss by dual action: inhibition of bone resorption and stimulation of new bone formation.

©2012The North American Menopause Society


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.